AL
ALXN

Airain Ltd’s Alexion Pharmaceuticals ALXN Stock Holding History

Airain Ltd’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$4.09M Sell
33,629
-41,865
-55% -$4.87M 0.18% 166
2017
Q1 		$9.15M Buy
75,494
+72,171
+2,172% +$9.3M 0.45% 60
2016
Q4 		$407K Sell
3,323
-98,932
-97% -$12.1M 0.03% 420
2016
Q3 		$12.5M Sell
102,255
-44,832
-30% -$5.77M 0.74% 26
2016
Q2 		$17.2M Buy
147,087
+40,420
+38% +$5.73M 0.99% 11
2016
Q1 		$14.8M Buy
+106,667
New +$15.7M 1.03% 12
2015
Q4 		– Sell
-13,111
Closed -$2.05M – 1119
2015
Q3 		$2.05M Sell
13,111
-30,083
-70% -$5.49M 0.12% 222
2015
Q2 		$7.81M Sell
43,194
-13,334
-24% -$2.3M 0.44% 59
2015
Q1 		$9.8M Sell
56,528
-6,538
-10% -$1.18M 0.6% 37
2014
Q4 		$11.7M Buy
63,066
+61,782
+4,812% +$11.4M 0.96% 8
2014
Q3 		$213K Sell
1,284
-68,210
-98% -$11.2M 0.01% 664
2014
Q2 		$10.9M Buy
+69,494
New +$11M 0.89% 14
2013
Q3 		– Sell
-57,725
Closed -$5.33M – 700
2013
Q2 		$5.33M Buy
+57,725
New +$5.56M 0.79% 14

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Airain Ltd's ALXN Position: Q2 2017 in Review

Airain Ltd reduced its Alexion Pharmaceuticals (ALXN) stake by 55% in Q2 2017, selling an estimated $4.87M and leaving 33,629 shares worth $4.09M. The position accounts for 0.18% of the portfolio, ranked #166.

Airain Ltd first reported a position in ALXN in Q2 2013 and has held it in 13 quarters since. The position peaked at $17.2M in Q2 2016. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Airain Ltd held 33,629 shares of Alexion Pharmaceuticals worth $4.09M as of Q2 2017.
  • Airain Ltd sold 41,865 Alexion Pharmaceuticals shares in Q2 2017, an estimated $4.87M.
  • Alexion Pharmaceuticals made up 0.18% of Airain Ltd's portfolio in Q2 2017, its #166 holding.
  • Airain Ltd first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 13 quarters since.
  • Airain Ltd's Alexion Pharmaceuticals position peaked at $17.2M in Q2 2016.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.